Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment

Journal of Surgical Oncology

Volumn 102, Issue 6, 2010, Pages 599-603

  Yeh, Chun Nan ^a   Chen, Tsung Wen ^a   Tseng, Jeng Hwei ^a   Liu, Yu Yin ^a   Wang, Shang Yu ^a   Tsai, Chun Yi ^a   Chiang, Kun Chun ^a   Hwang, Tsann Long ^a   Jan, Yi Yin ^a   Chen, Miin Fu ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

GIST; IMATINIB mesylate; surgery

Indexed keywords

IMATINIB; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; EXON; FEMALE; GASTRECTOMY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SMALL INTESTINE RESECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TREATMENT OUTCOME;

EID: 78349295591     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21630     Document Type: Article

References (22)

1. DeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
2. DeMatteo RP, Heinrich MC, El Rifai WM, et al.: Clinical management of gastrointestinal stromal tumors: Before and after STI-571. Hum Pathol 2002; 33: 466-477.
3. Yeh CN, Chen TW, Wu TJ, et al.: Treatment of 354 patients with metastatic gastrointestinal stromal tumor (GIST) of small bowel: Implications of imatinib mesylate. World J Gastroenterol 2006; 12: 3760-3765.
4. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580. (Pubitemid 28067289)
5. Rubin BP, Singer S, Tsao C, et al.: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-8121.
6. Antonescu CR, Sommer G, Sarran L, et al.: Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003; 9: 3329-3337.
7. Heinrich MC, Corless CL, Duensing A, et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710.
8. Yeh CN, Chen TW, Lee HL, et al.: Kinase mutations and imatinib mesylate response for 64 Taiwanese with metastatic GIST: Preliminary experience from Chang Gung memorial hospital. Ann Surg Oncol 2007; 14: 1123-1128.
9. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in metastatic gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
10. Verweij J, Casali PG, Zalcberg J, et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127-1134.
11. Demetri GD, Desai J, Fletcher JA, et al.: SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients with metastatic gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2004; 22: 3001.
12. Fletcher JA, Corless CL, Dimitrijevic S, et al.: Mechanisms of resistance to imatinib mesylate (IM) in metastatic gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2003; 21: 3275.
13. Chen LL, Trent JC, Wu EF, et al.: A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64: 5913-5919.
14. Debiec-Rychter M, Cools J, Dumez H, et al.: Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128: 270-279.
15. Antonescu CR, Besmer P, Guo T, et al.: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-4190.
16. Raut CP, Posner M, Desai J, et al.: Surgical management of metastatic gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325-2331.
17. Rutkowski P, Nowecki Z, Nyckowski P, et al.: Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304-311.
18. Andtbacka RHI, Ng CS, Scaife CL, et al.: Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14-24.
19. Gronchi A, Fiore M, Miselli F, et al.: Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in metastatic/metastatic GIST. Ann Surg 2007; 245: 341-346.
20. DeMatteo RP, Maki RG, Singer S, et al.: Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245: 347-352.
21. Heinrich MC, Corless CL, Demetri GD, et al.: Clinical and molecular studies of the effect of imatinibon metastatic aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24: 1195-1203.
22. Lux ML, Rubin BP, Biase TL, et al.: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791-795.